Rejuvenate Bio reposted this
Excited to announce we received $4M in funding today from California Institute for Regenerative Medicine (CIRM) to advance IND-enabling activities for RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). “DSP ACM is a rare, severe, life-threatening, and debilitating disease that typically manifests in young adults as a high risk of life-threatening ventricular arrhythmias, sudden cardiac death, and progression to heart failure,” said Daniel Oliver, CEO & Co-Founder, Rejuvenate Bio. “There is currently no disease modifying therapy for patients with this disease, and our gene therapy RJB-0402 addresses a significant unmet medical need.” Read the press release: https://lnkd.in/eigtVhtm
🌟 Congratulations, Rejuvenate Bio, on receiving $4M in funding from California Institute for Regenerative Medicine (CIRM) to advance RJB-0402 for DSP ACM treatment! Addressing such a critical medical need underscores your commitment to advancing gene therapy. #GeneTherapy #MedicalInnovation #DSPACM
Congrats Daniel Oliver Noah Davidsohn Deborah D. Ascheim, M.D. and team!
Many congrats to the Rejuvenate team for landing the funding!
Congratulations
Congrats to the entire Rejuvenate team!
Congratulations, Noah Davidsohn and team, well deserved! 🎉
Great news - congratulations, Noah Davidsohn and Daniel Oliver!
Congratulations Noah!! Wishing you the best!
Interesting gene therapy strategy (FGF21 in AAV8) to remediate to the unfit size of DSP gene. Go Rejuvenate Bio !